Wall Street expects a year-over-year decline in earnings on higher revenues when Acadia Pharmaceuticals (ACAD) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 5, might help the stock move higher if these key numbers are better ...

Acadia Pharmaceuticals (ACAD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a chan ...

Even though the economy appears uncertain, geopolitics are volatile and inflation is trending in the wrong direction, a new report from McKinsey & Company shows that businesses might miss out by delaying expansion.Companies that are building new ventures have seen relatively quick and decisive success, the report shows. It also revealed that new ventures launched by large businesses can now scale with 40% less capital. They’re also making more money faster. For ventures started in the last five years, 61% m ...

Acadia Pharmaceuticals (ACAD) closed the last trading session at $22.99, gaining 7.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $29.35 indicates a 27.7% upside potential.The average comprises 20 short-term price targets ranging from a low of $17.00 to a high of $39.00, with a standard deviation of $5.55. While the lowest estimate indicates a decline of 26.1% from the current ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is HCA Healthcare (HCA) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.HCA Healthcare is a member of the Medical sector. This group includes 955 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual st ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary duties to shareholders. If you currently own Acadia stock and acquired shares on or before September 9, 2019, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here t. ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying ACAD stock? Here’s what analysts think:Read This Next: Photo via ShutterstockLoading...Loading... ...

文章核心观点 - 文章旨在比较凯杰和阿卡迪亚制药两只股票对价值投资者的吸引力 [1] - 凯杰目前被认为是更具优势的价值投资选择 [7] 公司比较：Zacks评级 - 凯杰的Zacks评级为第2级（买入），阿卡迪亚制药的Zacks评级为第3级（持有） [3] - 凯杰的盈利前景改善程度可能强于阿卡迪亚制药 [3] 估值指标：市盈率 - 凯杰的远期市盈率为20.42，阿卡迪亚制药的远期市盈率为40.72 [5] - 凯杰的市盈增长比为2.52，阿卡迪亚制药的市盈增长比为7.49 [5] 估值指标：市净率与价值等级 - 凯杰的市净率为3.03，阿卡迪亚制药的市净率为4.37 [6] - 基于多项估值指标，凯杰的价值等级为B，阿卡迪亚制药的价值等级为C [6]

公司产品组合 - ACADIA Pharmaceuticals Inc 是一家生物制药公司 拥有两款商业化药物 [1] - 公司产品Nuplazid 用于治疗与帕金森病精神病相关的幻觉和妄想 [1] - 公司产品Daybue 适用于Rett综合征的治疗 [1]

公司核心事件 - Pomerantz LLP律师事务所正在对ACADIA Pharmaceuticals Inc及其部分高管和/或董事是否涉嫌证券欺诈或其他非法商业行为展开调查[1] - 调查背景源于公司于2025年9月24日发布的关于其药物ACP-101三期临床试验结果的公告[1] - 公告披露药物ACP-101在治疗普拉德-威利综合征患者贪食症的三期COMPASS PWS试验中未达到主要终点和任何次要终点[1] - 公司研发负责人表示鉴于该结果公司不打算继续研究鼻内卡贝托辛[1] - 此消息导致公司股价在2025年9月24日下跌每股234美元跌幅达992%收盘报每股2126美元[1] 相关律师事务所信息 - Pomerantz LLP在纽约芝加哥洛杉矶伦敦巴黎和特拉维夫设有办事处是公司证券和反垄断集体诉讼领域的领先律所之一[2] - 该律所由已故的亚伯拉罕·L·波梅兰兹创立被誉为集体诉讼领域的先驱拥有超过85年历史[2] - 该律所已为集体诉讼成员追回多项数百万美元的损害赔偿[2]